16:20 EDT Oruka Therapeutics (ORKA) files $1B mixed securities shelfSummer Sale - Claim 70% Off TipRanks Unlock powerful investing tools with Ti...
Oruka Therapeutics filed a $1B shelf registration backed by positive ORKA-001 clinical data. Clinical validation and $1B capital access signal runway stability, reducing funding risk for enterprise partnerships and research collaborations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ORKA:Disclaimer & DisclosureReport an Issue
Oruka Therapeutics: Strong Clinical Momentum and Pipeline Optionality Support Buy Rating and Unchanged $151 Price Target
Oruka Therapeutics reports Q2 EPS (55c), consensus (50c)
Oruka Therapeutics stock falls after hours after Fairmount sells a $300 million stake via SEC filing.
Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Orora (ORRAF) and…
In a report released yesterday, Chris Dendrinos from RBC Capital maintained a Buy rating on Ormat Techno, with a price target of…
16:18 EDT Unicycive Therapeutics (UNCY) files $150M mixed securities shelfClaim 55% Off TipRanksUnlock trusted, data-backed…
16:39 EDT Nuvectis Pharma (NVCT) files $200M mixed securities shelfSummer Sale - Claim 70% Off TipRanks Unlock powerful investing…
14:45 EDT Outlook jumps 24% to $1.64 after FDA approves wet AMD treatmentClaim 55% Off TipRanks Unlock powerful investing tools…
